Research and Development

Showing 15 posts of 9599 posts found.

kymriah

Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma

December 7, 2020 Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis

Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …
shutterstock_38078521

Jakafi outperforms best available therapy in steroid-refractory/dependent chronic graft-versus-host disease

December 7, 2020 Research and Development, Sales and Marketing Incyte, Jakafi, Novartis

The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …
janssen_latest_logo_on_sign_closer

Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia

December 7, 2020 Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica

Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 4, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Dupixent, EMA, UK, Vaccine, top ten

As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the …
shutterstock_159488225

New research links metformin to decreased mortality risk in female patients hospitalised with COVID-19

December 4, 2020 Medical Communications, Research and Development COVID-19, Vaccine, metformin

Researchers from the University of Minnesota Medical School (UMMS) and UnitedHealth Group have uncovered potential benefit of metformin, a generic …
shutterstock_103378880

IBM uncovers “precision phishing campaign” targeting global COVID-19 vaccine cold chain supply

December 4, 2020 Manufacturing and Production, Medical Communications, Research and Development COVID-19, Vaccine, ibm

US tech firm IBM has reported that it has identified attempts by unknown parties to hack and disrupt elements of …
shutter

Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population

December 3, 2020 Research and Development PharmaMar, jazz pharma, trial failure

Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …
nasal_spray

Drug-free nasal spray could prevent COVID-19 infection, promising data show

December 3, 2020 Research and Development COVID-19, Nasal Spray, auris medical

Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could …
covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

December 2, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Image credit: CDC, Top 5, Vaccine

EMA receives Pfizer and BioNTech’s filing for conditional approval of COVID-19 vaccine in Europe – Published on 01/12/20
fdaoutsideweb

FDA greenlights Gavreto for advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in over-12s

December 2, 2020 Research and Development, Sales and Marketing FDA, Gavreto, Roche

The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …
janssen_latest_logo_on_sign

European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo

December 2, 2020 Research and Development, Sales and Marketing Europe, Janssen, Tremfya

The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …
shutter

Ovid’s Angelman syndrome therapy falls short at Phase 3

December 2, 2020 Research and Development Angelman syndrome, Ovid

Ovid Therapeutics has revealed disappointing results for its therapy OV101 (gaboxadol) in the treatment of Angelman syndrome, admitting that it failed …
88222

UK becomes first nation to approve Pfizer and BioNTech’s COVID-19 vaccine

December 2, 2020 Research and Development, Sales and Marketing COVID-19, Pfizer, UK, Vaccine

The UK has become the first country worldwide to authorise Pfizer and BioNTech’s promising COVID-19 vaccine, the UK Government has …
pharmafile_autumn_2020_front_cover

The Autumn 2020 edition of Pharmafile is available to read for free online now!

December 1, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing infectious diseases, pharmafile, rare disease, respiratory

The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 has seen almost unprecedented disruption …
shutterstock_273326141

Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies

December 1, 2020 Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Wren Therapeutics

Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in tackling neurodegenerative diseases known as …
The Gateway to Local Adoption Series

Latest content